ALFA FinderBSE filing, NSE: TRIMURTHI. Summary written from the filing by ALFA Finder's alert engine.
Novelix Pharmaceuticals Ltd: key numbers
- Share price
- ₹69.49
- Market cap
- ₹122.4 Cr
- Revenue (annual)
- ₹132.3 Cr
- Net profit (annual)
- ₹2.56 Cr
- P/E (TTM)
- 26.3×Sector 65.7×
- Promoter holding
- 54.29%+3.72% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novelix Pharmaceuticals Ltd
All →Novelix Pharmaceuticals Business Update
Novelix Pharmaceuticals entered a supply agreement with axabio NV, Belgium, to procure natural astaxanthin. No specific contract value was disclosed.
Novelix Pharmaceuticals Management Change
Novelix Pharmaceuticals redesignated Venkateshwarlu Pulluru from Whole-Time Director to Non-Executive Director from 11 November 2026. He stays on the Board but gives up executive duties.
Novelix Pharmaceuticals Q2 FY27 Results: Net Profit ₹1.6 Cr, Up 220.0% YoY
Novelix Pharmaceuticals Ltd reported revenue from operations of ₹44.7 Cr (+22.8% YoY) and net profit of ₹1.6 Cr (+220.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.6 Cr · +220.0% YoY
Novelix Pharmaceuticals Board Meeting Date
Novelix Pharmaceuticals has given prior intimation of a board meeting on 11 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The trading window stays closed until forty-eight hours after the meeting.
Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Novelix Pharmaceuticals Management Change
Novelix Pharmaceuticals announced the appointment of Mr. Gnana Prakash Gattu as Whole Time Director, approved by shareholders at the company's 32nd Annual General Meeting.
Other other announcement announcements
All →Exim Routes Other Announcement
Exim Routes filed CARE Ratings' IPO proceeds monitoring report for quarter ended September 2026. It reports nil deviation from objects but flags vendor changes and fund interchanges.
Gulf Lloyds (India) Other Announcement
Gulf Lloyds reported no deviation in its IPO proceeds use for the half year ended 30 September 2026. The Audit Committee reviewed the statement.
Inter State Oil Carrier Other Announcement
Inter State Oil Carrier declared related party disclosure non-applicable for half-year ended September 2026. Paid-up capital and net worth are below Regulation 15(2) limits.
Ruchira Papers Other Announcement
Ruchira Papers reconstituted its Stakeholders Relationship Committee with effect from 13 November 2026. Deepan Garg joined as a new member.
Switching Technologies Gunther Other Announcement
Switching Technologies Gunther disclosed half-year related party transactions to September 2026 under Reg 23(9). It is routine periodic disclosure, not a single new deal.
Sai Silks (Kalamandir) Other Announcement
CARE Ratings' monitoring report on Sai Silks' Rs.600 crore IPO proceeds shows no deviation from objects. It notes delays in warehouse spending, with Rs.20.27 crore unutilised.